寡核苷酸及其在抗乙型肝炎和丁型肝炎病毒中的应用
By using oligonucleotides of specific length and modification to complement the hepatitis B virus genome and target viral RNA, the problem of poor efficacy of existing therapies has been solved, achieving effective inhibition of HBsAg and HBeAg and functional cure of hepatitis B.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- ZHEJIANG PALOALTO PHARMA TECH CO LTD
- Filing Date
- 2020-11-16
- Publication Date
- 2026-07-17
AI Technical Summary
Existing treatments for hepatitis B and hepatitis D are not very effective and cannot effectively suppress hepatitis B virus antigens HBsAg and/or HBeAg, leading to chronic infection that is difficult to control. Existing drugs have side effects and cannot achieve functional cure.
Modified or unmodified oligonucleotides with a length of 24-40 nt, having specific core sequences and nucleoside internucleotide modifications such as thiophosphate bonds, can complement the hepatitis B virus genome, target viral RNA, and inhibit the expression of viral gene products.
It significantly inhibits hepatitis B virus DNA replication and reduces serum HBsAg and HBeAg concentrations, showing the potential for functional cure of hepatitis B and is suitable for use in combination with existing therapies.
Smart Images
Figure QLYQS_1 
Figure BDA0002781184070000121 
Figure BDA0002781184070000131